Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) 2006-06-01

Investigation of the pronounced synergism between prostaglandin E2 and other constrictor agents on rat femoral artery.

Gloria H Y Hung, Robert Leslie Jones, Francis F Y Lam, Kam-Ming Chan, Hiroyoshi Hidaka, Masaaki Suzuki, Yasuharu Sasaki

Index: Prostaglandins Leukot. Essent. Fatty Acids 74 , 401-15, (2006)

Full Text: HTML

Abstract

This study investigates the pronounced synergism between the weak contractile action of prostaglandin E(2) (PGE(2)) and strong actions of phenylephrine, U-46619 and K(+) on rat isolated femoral artery. The potency ranking for synergism was SC-46275 (prostanoid receptor agonist selectivity: EP(3)>>EP(1))=sulprostone (EP(3)>EP(1))>17-phenyl PGE(2) (EP(1)>EP(3)). The novel EP(3) antagonist L-798106 (0.2-1microM) blocked the enhanced action of sulprostone (pA(2)=7.35-8.10), while the EP(1) antagonist SC-51322 (1microM) did not (pA(2)<6.0). Matching responses to priming agent and priming agent/sulprostone were similarly suppressed by nifedipine (300nM) and the selective Rho-kinase inhibitors H-1152 (0.1-1microM) and Y-27632 (1-10microM). Our findings implicate an EP(3) receptor in the prostanoid component of contractile synergism. While the synergism predominantly operates through a Ca(2+) influx-Rho-kinase pathway, the EP(3) receptor does not necessarily transduce via Rho-kinase.